Q-omics provides the consensus-scored TECRL profile across patient tissues and cancer cell-line models. TECRL expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, TECRL is differentially expressed in 3, with the highest sampling consensus in THCA. Additionally, TECRL RNA expression shows 6,683 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight COAD, THCA, and STAD as cancer lineages where TECRL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TECRL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TECRL survival associations across molecular data types. TECRL RNA expression shows survival associations in the most cancer types (19), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TECRL RNA expression–survival associations across cancer types. High TECRL expression shows unfavorable associations in COAD, KICH, UVM, DLBC and UCEC, but favorable associations in ESCA. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for TECRL RNA expression.
This table summarizes TECRL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for TECRL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TECRL shows lower tumor expression in THCA and HNSC and higher tumor expression in LIHC. The THCA box plot shows higher TECRL RNA expression in normal versus tumor tissue (log2 FC = −0.303, t-test p = .003).
This table shows molecular features associated with TECRL in patient tissues and cancer cell lines. In patient samples, TECRL shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, TECRL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
